QPS Expands Phase 1 and Bioanalytical Capability by Acquisition of Bioserve, IndiaBy Qps Llc, PRNE
Tuesday, January 25, 2011
NEWARK, Delaware and HYDERABAD, India, January 26, 2011 - QPS, LLC, a leading full-service GLP/GCP-compliant contract research
organization providing testing services to support preclinical and clinical
research and development, announced the acquisition of a majority stake in
Bioserve Clinical Research. Bioserve, a full service phase 1 CRO
headquartered in Hyderabad, India, will be known as QPS-Bioserve India.
QPS is a global CRO supporting drug discovery and development since 1995.
Its five areas of expertise include: Preclinical DMPK/Tox, Bioanalytical,
Translational Medicine, Early Stage Clinical and Late Stage Clinical
Bioserve is an ISO 9001:2008 certified organization providing world-class
clinical research services to sponsors across the globe. Its infrastructure
includes a 92-bed clinical unit for conducting phase I studies and a
bioanalytical lab equipped with multiple LC/MS/MS systems for small molecule
bioanalysis. Over the past 6 years, it has conducted over 500 studies, with
numerous product approvals, and has been inspected by the USFDA, UK MHRA, WHO
and Indian DCGI.
"This new partnership further expands QPS' global range of linearly
integrated services," said Ben Chien, PhD, Chairman, President and CEO of
QPS. "With access to Bioserve's additional resources, our customers will have
the heightened benefits of a third more phase I beds, bringing our total to
400; greater bioanalytical capacity; and access to another facility, located
in India, with a reputation for outstanding performance and a record of
timely approvals. Furthermore, current customers will be reassured to learn
that Mr. Suneil Reddy will remain as Managing Director."
The company has been growing at a rate of over 50% per year, with a
current team of over 100 employees. Clients include large Indian as well as
Multinational pharmaceutical firms. Bioserve's promoters - the founders of
Vijaya Diagnostic Centre, one of the largest diagnostic health care companies
in India - bring a wealth of 30 years experience in the healthcare and
clinical domain, combined with a passion for quality.
QPS provides GLP/GCP-compliant preclinical and clinical research services
to pharmaceutical and biotechnology clients worldwide in the areas of
Bioanalysis, Drug Metabolism and Pharmacokinetics, Translational Medicine,
and Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Bioanalysis
and Preclinical testing facilities at its Newark, DE headquarters; in
Groningen, the Netherlands; and in Taipei, Taiwan. Early-phase clinical
facilities are located in Springfield, MO; Taipei, Taiwan; and Groningen, the
Netherlands. Business development offices are maintained in the US, Europe,
Bioserve was established in 2004 as a regulatory class CRO, offering
end-to-end services, primarily catering to the needs of the generic
pharmaceutical industry. Bioserve focuses on sponsors' requirements -
quality, compliance, and time and cost effectiveness - while remaining
reliable and responsive. Bioserve's services include Phase I &
Bioavailability/Bioequivalence studies, PK in Patient Populations,
Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic
Imaging, Clinical Trial Management and Regulatory Affairs.
QPS: Ben Chien, PhD, Chairman, President & CEO of QPS Holdings, LLC, +-1-302-369-5110 DE office, or + 1-650-599-9445 CA office, ben.chien at qps-usa.com; Bioserve Clinical Research (P) Ltd, Suneil S. Reddy, Managing Director, India, Tel: +91-40-2377-0873, or +91-40-2377-0874, Fax: +91-40-2377-0877, suneil at bioserve.co.in, For business inquiries, bd at bioserve.co.in, For general inquiries, info at bioserve.co.in
Tags: Delaware, Delaware And Hyderabad, India, January 26, Newark, Qps Llc